IGC Pharma, Inc.IGCNYSE
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +41.58% | +25.98% | +11.86% | +20.59% | -53.64% |
| Gross Profit Growth | +13.79% | +0.00% | +516.00% | -5.52% | -50.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +39.97% | +21.83% | +15.65% | +14.03% | +19.01% |
| Weighted Average Shares Diluted Growth | +39.97% | +21.83% | +15.65% | +14.03% | +19.01% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -35.77% | -54.63% | +97.44% | +134.18% | -53.41% |
| Inventory Growth | -42.72% | -27.37% | -13.98% | -10.66% | -56.42% |
| Asset Growth | -37.18% | -19.37% | -11.66% | -25.02% | -6.04% |
| Book Value per Share Growth | -62.62% | -43.25% | -25.24% | -32.36% | -7.83% |
| Debt Growth | +5.50% | +4.47% | -31.61% | -40.24% | -68.93% |
| R&D Expense Growth | -27.68% | -5.65% | +16.61% | -4.27% | +73.17% |
| SG&A Expenses Growth | -25.48% | -45.88% | -57.54% | -27.66% | +35.45% |